GEFTINAT — 250MG

PRODUCT DETAILS
Trade name : Geftinat
Active component : Gefitinib
Strength : 250mg
Pack : 30 tablets in a container
Manufactured by : Natco pharma
Category : Anti-neoplastic drug
DESCRIPTION
Geftinat tablets are categorized as kinase inhibitor, which exhibits anti-cancer activity by undergoing mechanism like protein kinase inhibition, the main ingredient which is used as Gefitinib Iressa. Geftinat contains an active compound known as Gefitinib Iressa which is chemically known as anilinoquinazoline which contains anti-neoplastic effects. Geftinat is a FDA approved product, manufactured by Natco pharma
INDICATION
Geftinat is considered as first line therapy in non-small cell lung carcinoma in metastatic stage, tumor cell containing epidermal growth factor receptors like exon 19 deletion or exon 21 substitution mutations which is identified by FDA approved test.
PHARMACOLOGICAL ACTION
Geftinat containing Gefitinib causes unstable inhibition of tyrosine kinase and triggering variation of EGFR, hindering the autophosphorylation of tyrosine debris related with receptor, through prohibits following signaling and blockade EGFR dependent multiplication
ADME PROPERTIES
The mean bioavailability of Gefitinib Iressa is 60% The peak plasma concentration time of Geftinat is reaches within 3 to 7 hours after drug intake Gefitinib Iressa is distributed throughout the body and causes steady state volume of distribution in 1400L The human plasma protein bound of Gefitinib is occurs as 90%.
LIMITATION OF USE;
The potency of Gefitinib Iressa has been evaluated in patients with long lasting non-small cell lung carcinoma in whose tumor cells have epidermal growth factor receptor apart from exon 19 deletions or exon 21 alternative mutations.
WARNING AND PRECAUTIONS
Interstitial lung disease: In this case, Geftinat therapy is discontinue and rapidly examine for ILD in any patients who have acute respiratory problems. Liver toxicity: Patient receiving Geftinattablets have a chance to elevate AST & ALT levels and increased bilirubin levels cause hepatotoxicity and to recover from this condition discontinue the therapy. Gastrointestinal perforation: For this condition, stop the therapy permanently. Persistent diarrhea: Discontinue the therapy with Geftinat Ocular disorders: Ocular disorders like corneal erosion, aberrant eyelash growth may occur during the therapy of Geftinat, discontinue the Geftinat therapy.
DRUG INTERACTION
Strong CYP3A4 inducers:
In combination with Geftinat tablets causes increasing the metabolism of Gefitinib Iressa and reducing the plasma concentration of Gefitinib. In this condition the dosage of Geftinat is increased to 500mg and followed by 250mg for 7 days after stopping the CYP3A4 inducers like phenytoin, rifampicin or tricyclic anti depressants.
UNDESIRABLE EFFECTS
The major adverse effect of Geftinat tablets occurs as; Liver toxicity, Gastrointestinal perforation, Severe diarrhea, Bullous & expoliative skin disorders, Ocular disorders, Interstitial lung disease.
The most common side effects are; Headache, Diarrhea, Fatigue, Respiratory failure occurs due to pneumonia & pulmonary embolism, Geftinat Nausea, Vomiting, Skin reactions, Nail disorders, Stomatitis, Loss of appetite,, Conjunctivitis, Blepharitis, Dry eye, Mucosal inflammation, tongue ulceration, eye irritation, eyelid Pruritus, edema, Elevation of AST, ALT, Proteinuria, Hemorrhagic cystitis, Cutaneous vasculitis .
LACTATION
durimng treat of Geftinat .Breast feeding should not be recommended.
STORAGE
The storage of Geftinat tablet container should be kept at 20℃ to 25℃ (68℉ to 77℉). Protect the container from moisture, heat and light.
contact Details
Phone :+91–9987711567
Email :applepharmaceutical@gmail.com
Email :info@myapplepharma.com
